Perspective Therapeutics
CATX
29 hedge funds and large institutions have $1.56M invested in Perspective Therapeutics in 2017 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 6 increasing their positions, 0 reducing their positions, and 2 closing their positions.
150% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 2
12% more funds holding
Funds holding: 26 → 29 (+3)
0.06% more ownership
Funds ownership: 0.65% → 0.71% (+0.06%)
16% less capital invested
Capital invested by funds: $1.86M → $1.56M (-$301K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$55.7K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$30K |
| 3 |
TSS
Two Sigma Securities
New York
|
+$26.8K |
| 4 |
CWM
Cahaba Wealth Management
Atlanta,
Georgia
|
+$25.6K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$12.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PNC Financial Services Group
Pittsburgh,
Pennsylvania
|
-$10K |
| 2 |
SIA
Starfire Investment Advisers
Southfield,
Michigan
|
-$10K |
CATX Hedge Fund Activity: Q4 2017 in Review
29 of the 4,419 institutional investors tracked by Wall St. Rank reported a position in Perspective Therapeutics (CATX) for Q4 2017, worth a combined $1.56M — down 16% from $1.86M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new CATX positions and 2 closed out — a net gain of 3 holders — while 6 added to existing stakes and 0 trimmed.
The largest buyer was Susquehanna International Group, adding an estimated $55.7K. The largest seller was PNC Financial Services Group, exiting entirely with an estimated $10K sold.
- 29 institutional investors held Perspective Therapeutics (CATX) as of Q4 2017, up from 26 in Q3 2017.
- Funds reported $1.56M of Perspective Therapeutics stock for Q4 2017, down 16% quarter-over-quarter.
- 5 funds opened new Perspective Therapeutics positions in Q4 2017 and 2 closed out, a net change of +3 holders.
- The largest Perspective Therapeutics buyer in Q4 2017 was Susquehanna International Group, an estimated $55.7K added.
- The largest Perspective Therapeutics seller in Q4 2017 was PNC Financial Services Group, an estimated $10K sold.
Based on aggregated 13F filings for Q4 2017.